To the full analysis
Dr. Reddy's Laboratories stock: growth
RDYDr. Reddy's Laboratories reported $3.76B in revenue for fiscal 2026, up 8.6% on the prior year, up 168% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
9.3%
per year from 2007 to 2026, per share 9%
Earnings (Annual rate)
8.6%
per year from 2007 to 2026, per share −0.4%
Free cash flow (Annual rate)
8.3%
per year from 2007 to 2026, per share 8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 168.0% | 8.6% | 9.3% |
| Revenue per share | 167.8% | 8.9% | 9.0% |
| Earnings | 186.8% | 8.5% | 8.6% |
| Earnings per share | 21.0% | −7.5% | −0.4% |
| Free cash flow | 6.8% | 2.0% | 8.3% |
| Free cash flow per share | 6.7% | 2.2% | 8.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $693.53M | $99.37M | $75.3M |
| 2008 | $531.5M | $49.72M | −$6.88M |
| 2009 | $738.08M | −$54.93M | −$2.72M |
| 2010 | $746.96M | $11.35M | $95.05M |
| 2011 | $793.9M | $117.34M | −$38.23M |
| 2012 | $1.03B | $151.59M | $80.41M |
| 2013 | $1.24B | $178.32M | $63.57M |
| 2014 | $1.4B | $228.65M | $93.92M |
| 2015 | $1.58B | $235.74M | $103.16M |
| 2016 | $1.64B | $212.72M | $280.3M |
| 2017 | $1.5B | $127.96M | −$206.95M |
| 2018 | $1.51B | $104.23M | $74.25M |
| 2019 | $1.64B | $199.77M | $225.47M |
| 2020 | $1.86B | $207.24M | $252.18M |
| 2021 | $27.16M | $2.47M | $245.97M |
| 2022 | $2.28B | $250.5M | $96.29M |
| 2023 | $2.61B | $479.01M | $425.25M |
| 2024 | $2.97B | $591.86M | $191.3M |
| 2025 | $3.46B | $601M | $127.87M |
| 2026 | $3.76B | $479.22M | $341.21M |
Revenue by region
Where Dr. Reddy's Laboratories Limited generates its revenue.
- United States33%
- India Country18%
- Russia Country10%
- Other39%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2024 | 2025 | 2026 | Share 2026 | |
|---|---|---|---|---|
| United States | $1.44B | $1.59B | $1.25B | 33.4% |
| India Country | $515.21M | $593.41M | $685.95M | 18.3% |
| Russia Country | $237.03M | $275.9M | $369.74M | 9.8% |
| Other | $774.05M | $1B | $1.45B | 38.5% |
| Total revenue | $2.97B | $3.46B | $3.76B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 10 Jul 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.